| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biopsy, Needle | 15 | 2013 | 1363 | 1.670 |
Why?
|
| Radiography, Interventional | 13 | 2011 | 305 | 1.550 |
Why?
|
| Tomography, X-Ray Computed | 27 | 2013 | 7551 | 1.110 |
Why?
|
| Embolization, Therapeutic | 10 | 2009 | 551 | 0.930 |
Why?
|
| Yttrium Radioisotopes | 3 | 2007 | 178 | 0.780 |
Why?
|
| Hepatic Artery | 6 | 2009 | 240 | 0.760 |
Why?
|
| Liver Neoplasms | 14 | 2020 | 4557 | 0.740 |
Why?
|
| Urinary Fistula | 3 | 2004 | 27 | 0.700 |
Why?
|
| Chemoembolization, Therapeutic | 4 | 2007 | 181 | 0.650 |
Why?
|
| Ureteral Diseases | 3 | 2004 | 16 | 0.530 |
Why?
|
| Biopsy | 4 | 2012 | 3443 | 0.460 |
Why?
|
| Needles | 2 | 2005 | 107 | 0.450 |
Why?
|
| Vascular Fistula | 2 | 2004 | 41 | 0.440 |
Why?
|
| Pelvic Neoplasms | 2 | 2004 | 189 | 0.420 |
Why?
|
| Online Systems | 1 | 2011 | 27 | 0.410 |
Why?
|
| Vena Cava Filters | 3 | 2004 | 88 | 0.390 |
Why?
|
| Risk Management | 1 | 2011 | 107 | 0.380 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2011 | 220 | 0.360 |
Why?
|
| Catheter Ablation | 2 | 2005 | 620 | 0.350 |
Why?
|
| User-Computer Interface | 1 | 2011 | 286 | 0.350 |
Why?
|
| Hepatectomy | 5 | 2020 | 1011 | 0.310 |
Why?
|
| Gastrointestinal Stromal Tumors | 2 | 2009 | 297 | 0.310 |
Why?
|
| Pneumothorax | 4 | 2011 | 153 | 0.300 |
Why?
|
| Transplantation Tolerance | 1 | 2006 | 15 | 0.290 |
Why?
|
| Aged | 42 | 2020 | 70117 | 0.290 |
Why?
|
| Isoantigens | 1 | 2006 | 62 | 0.290 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 585 | 0.290 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2016 | 255 | 0.280 |
Why?
|
| Peripheral Nerves | 1 | 2006 | 159 | 0.270 |
Why?
|
| Pneumothorax, Artificial | 1 | 2005 | 4 | 0.270 |
Why?
|
| Splenic Artery | 1 | 2005 | 50 | 0.270 |
Why?
|
| Splenic Diseases | 1 | 2005 | 56 | 0.260 |
Why?
|
| Hematologic Neoplasms | 2 | 2010 | 1870 | 0.260 |
Why?
|
| Middle Aged | 43 | 2020 | 86204 | 0.260 |
Why?
|
| Lung Diseases | 1 | 2010 | 717 | 0.250 |
Why?
|
| Radiographic Image Enhancement | 1 | 2007 | 402 | 0.240 |
Why?
|
| Drug Carriers | 1 | 2005 | 327 | 0.240 |
Why?
|
| Pulmonary Embolism | 2 | 2004 | 329 | 0.240 |
Why?
|
| Venous Thrombosis | 2 | 2004 | 384 | 0.240 |
Why?
|
| Thromboembolism | 1 | 2004 | 155 | 0.230 |
Why?
|
| Iliac Artery | 2 | 2002 | 108 | 0.230 |
Why?
|
| Spleen | 1 | 2005 | 676 | 0.230 |
Why?
|
| Radiography, Abdominal | 1 | 2004 | 120 | 0.220 |
Why?
|
| Lung Neoplasms | 7 | 2013 | 11538 | 0.220 |
Why?
|
| Adult | 35 | 2016 | 77950 | 0.220 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2007 | 1248 | 0.220 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2005 | 2326 | 0.220 |
Why?
|
| Microspheres | 4 | 2007 | 210 | 0.220 |
Why?
|
| Graft Survival | 1 | 2006 | 1062 | 0.220 |
Why?
|
| Male | 43 | 2020 | 123000 | 0.210 |
Why?
|
| Lung | 2 | 2010 | 3151 | 0.210 |
Why?
|
| Radiopharmaceuticals | 1 | 2007 | 1301 | 0.210 |
Why?
|
| Female | 47 | 2020 | 141928 | 0.200 |
Why?
|
| Pelvis | 1 | 2003 | 362 | 0.200 |
Why?
|
| Liver | 4 | 2007 | 2961 | 0.200 |
Why?
|
| Mediastinal Diseases | 1 | 2002 | 56 | 0.200 |
Why?
|
| Neoplasms | 8 | 2020 | 15193 | 0.200 |
Why?
|
| Humans | 63 | 2021 | 261506 | 0.200 |
Why?
|
| Kidney Neoplasms | 2 | 2005 | 3022 | 0.200 |
Why?
|
| Ultrasonography | 2 | 2005 | 1863 | 0.200 |
Why?
|
| Mediastinal Neoplasms | 1 | 2005 | 423 | 0.200 |
Why?
|
| Pancreatic Diseases | 1 | 2002 | 108 | 0.190 |
Why?
|
| Colorectal Neoplasms | 2 | 2007 | 3578 | 0.190 |
Why?
|
| Lymphadenopathy | 1 | 2021 | 90 | 0.180 |
Why?
|
| Portal Vein | 4 | 2007 | 355 | 0.170 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2002 | 412 | 0.170 |
Why?
|
| Retrospective Studies | 19 | 2016 | 37905 | 0.170 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 2 | 2011 | 96 | 0.170 |
Why?
|
| Optical Imaging | 1 | 2020 | 157 | 0.160 |
Why?
|
| Thrombocytopenia | 1 | 2003 | 846 | 0.150 |
Why?
|
| Radiology, Interventional | 2 | 2011 | 138 | 0.150 |
Why?
|
| Microscopy, Confocal | 1 | 2020 | 663 | 0.150 |
Why?
|
| Treatment Outcome | 16 | 2016 | 32848 | 0.150 |
Why?
|
| Osteosarcoma | 1 | 2004 | 929 | 0.150 |
Why?
|
| Stents | 2 | 2002 | 1096 | 0.150 |
Why?
|
| Microscopy, Fluorescence | 1 | 2020 | 769 | 0.150 |
Why?
|
| Radiography | 4 | 2005 | 1904 | 0.150 |
Why?
|
| Ultrasonography, Interventional | 2 | 2011 | 429 | 0.140 |
Why?
|
| Muscle, Skeletal | 1 | 2003 | 1270 | 0.140 |
Why?
|
| Graft Occlusion, Vascular | 2 | 1999 | 118 | 0.140 |
Why?
|
| Chest Tubes | 2 | 2007 | 101 | 0.140 |
Why?
|
| Image-Guided Biopsy | 2 | 2020 | 327 | 0.130 |
Why?
|
| Aged, 80 and over | 16 | 2013 | 29902 | 0.130 |
Why?
|
| Ablation Techniques | 1 | 2016 | 148 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 4367 | 0.130 |
Why?
|
| Metastasectomy | 1 | 2016 | 200 | 0.120 |
Why?
|
| Antineoplastic Agents | 5 | 2011 | 14289 | 0.110 |
Why?
|
| Diagnostic Imaging | 1 | 2021 | 1162 | 0.110 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2009 | 600 | 0.110 |
Why?
|
| Carcinoid Tumor | 2 | 2005 | 280 | 0.110 |
Why?
|
| Medical Staff Privileges | 1 | 2011 | 10 | 0.100 |
Why?
|
| Niacinamide | 1 | 2013 | 421 | 0.100 |
Why?
|
| Bone Neoplasms | 1 | 2004 | 2576 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 2 | 2013 | 2330 | 0.100 |
Why?
|
| Head and Neck Neoplasms | 1 | 2007 | 3976 | 0.100 |
Why?
|
| Systems Integration | 1 | 2011 | 76 | 0.100 |
Why?
|
| Aircraft | 1 | 2011 | 28 | 0.100 |
Why?
|
| Catheterization | 2 | 2007 | 410 | 0.100 |
Why?
|
| Respiration Disorders | 1 | 2011 | 45 | 0.100 |
Why?
|
| Gene Transfer Techniques | 2 | 2012 | 716 | 0.100 |
Why?
|
| Medical Oncology | 2 | 2012 | 1423 | 0.100 |
Why?
|
| Cryptogenic Organizing Pneumonia | 1 | 2010 | 17 | 0.090 |
Why?
|
| Radiography, Thoracic | 1 | 2013 | 462 | 0.090 |
Why?
|
| Postoperative Complications | 4 | 2020 | 5542 | 0.090 |
Why?
|
| Phenylurea Compounds | 1 | 2013 | 580 | 0.090 |
Why?
|
| Biomarkers, Tumor | 4 | 2013 | 10331 | 0.090 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2010 | 68 | 0.090 |
Why?
|
| Health Services Research | 1 | 2011 | 233 | 0.090 |
Why?
|
| Travel | 1 | 2011 | 190 | 0.090 |
Why?
|
| Thrombosis | 2 | 1999 | 781 | 0.090 |
Why?
|
| Bronchial Arteries | 1 | 2009 | 11 | 0.090 |
Why?
|
| Adolescent | 9 | 2011 | 31252 | 0.090 |
Why?
|
| Lung Diseases, Fungal | 1 | 2010 | 124 | 0.090 |
Why?
|
| Hemoptysis | 1 | 2009 | 36 | 0.090 |
Why?
|
| Informed Consent | 1 | 2012 | 419 | 0.090 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2010 | 123 | 0.080 |
Why?
|
| Respiration | 1 | 2011 | 447 | 0.080 |
Why?
|
| Thoracic Neoplasms | 2 | 2009 | 337 | 0.080 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2011 | 604 | 0.080 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2007 | 76 | 0.080 |
Why?
|
| Swine | 4 | 2007 | 1541 | 0.080 |
Why?
|
| Genetic Therapy | 3 | 2012 | 1616 | 0.080 |
Why?
|
| Fluoroscopy | 2 | 2008 | 232 | 0.080 |
Why?
|
| Radiotherapy Dosage | 2 | 2005 | 3842 | 0.080 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2010 | 247 | 0.080 |
Why?
|
| Nanoparticles | 1 | 2012 | 554 | 0.080 |
Why?
|
| Adenoviridae | 2 | 2003 | 1459 | 0.070 |
Why?
|
| Biomedical Research | 2 | 2012 | 806 | 0.070 |
Why?
|
| Precision Medicine | 2 | 2013 | 1154 | 0.070 |
Why?
|
| Splenic Neoplasms | 1 | 2008 | 119 | 0.070 |
Why?
|
| Hepatomegaly | 1 | 2007 | 69 | 0.070 |
Why?
|
| Polyvinyl Alcohol | 2 | 2005 | 19 | 0.070 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2006 | 88 | 0.070 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2007 | 305 | 0.070 |
Why?
|
| Swine, Miniature | 1 | 2006 | 67 | 0.070 |
Why?
|
| Nitrates | 1 | 1986 | 43 | 0.070 |
Why?
|
| Thoracic Diseases | 1 | 2006 | 31 | 0.070 |
Why?
|
| Cetuximab | 1 | 2007 | 472 | 0.070 |
Why?
|
| Penile Erection | 1 | 1986 | 86 | 0.070 |
Why?
|
| Carcinoma, Islet Cell | 1 | 2005 | 35 | 0.070 |
Why?
|
| Nerve Regeneration | 1 | 2006 | 105 | 0.070 |
Why?
|
| Immunocompromised Host | 1 | 2010 | 698 | 0.070 |
Why?
|
| Disease-Free Survival | 4 | 2016 | 10001 | 0.070 |
Why?
|
| Electrodes | 1 | 2005 | 116 | 0.070 |
Why?
|
| Headache | 1 | 1986 | 163 | 0.060 |
Why?
|
| Leg Bones | 1 | 2004 | 11 | 0.060 |
Why?
|
| Societies, Medical | 1 | 2011 | 1335 | 0.060 |
Why?
|
| Urinary Bladder Fistula | 1 | 2004 | 13 | 0.060 |
Why?
|
| Aneurysm | 1 | 2005 | 94 | 0.060 |
Why?
|
| Endovascular Procedures | 1 | 2011 | 516 | 0.060 |
Why?
|
| ErbB Receptors | 1 | 2013 | 2295 | 0.060 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2005 | 222 | 0.060 |
Why?
|
| Radius | 1 | 2004 | 42 | 0.060 |
Why?
|
| Humerus | 1 | 2004 | 53 | 0.060 |
Why?
|
| Thorax | 1 | 2006 | 213 | 0.060 |
Why?
|
| Urethral Diseases | 1 | 2004 | 36 | 0.060 |
Why?
|
| Outpatients | 1 | 2007 | 462 | 0.060 |
Why?
|
| Hypertension, Portal | 1 | 2005 | 124 | 0.060 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2008 | 690 | 0.060 |
Why?
|
| Clinical Trials as Topic | 2 | 2012 | 3719 | 0.060 |
Why?
|
| Ultraviolet Rays | 1 | 2006 | 575 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 1823 | 0.060 |
Why?
|
| Ilium | 1 | 2004 | 54 | 0.060 |
Why?
|
| Bevacizumab | 1 | 2007 | 938 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2013 | 5319 | 0.060 |
Why?
|
| Wounds, Penetrating | 1 | 2004 | 89 | 0.060 |
Why?
|
| Renal Dialysis | 2 | 1999 | 945 | 0.060 |
Why?
|
| Jugular Veins | 1 | 2003 | 107 | 0.050 |
Why?
|
| Platelet Transfusion | 1 | 2003 | 156 | 0.050 |
Why?
|
| Survival Rate | 4 | 2016 | 12221 | 0.050 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2003 | 164 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2006 | 2803 | 0.050 |
Why?
|
| Subclavian Vein | 1 | 1991 | 35 | 0.050 |
Why?
|
| Equipment Design | 1 | 2005 | 1204 | 0.050 |
Why?
|
| Platelet Count | 1 | 2003 | 490 | 0.050 |
Why?
|
| Fatty Acids | 1 | 2005 | 448 | 0.050 |
Why?
|
| Child | 5 | 2007 | 29154 | 0.050 |
Why?
|
| Neoplasms, Second Primary | 1 | 2010 | 1350 | 0.050 |
Why?
|
| Peptide Library | 1 | 2002 | 158 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2004 | 726 | 0.050 |
Why?
|
| Vascular Patency | 2 | 1999 | 218 | 0.050 |
Why?
|
| Radiotherapy | 2 | 2005 | 1824 | 0.050 |
Why?
|
| Blood Vessels | 1 | 2002 | 217 | 0.050 |
Why?
|
| Urinary Bladder | 1 | 2004 | 575 | 0.050 |
Why?
|
| Lower Extremity | 1 | 2003 | 299 | 0.050 |
Why?
|
| Piperazines | 1 | 2009 | 2101 | 0.050 |
Why?
|
| Gallbladder Neoplasms | 1 | 2003 | 245 | 0.050 |
Why?
|
| Lymphatic Metastasis | 1 | 2010 | 4844 | 0.050 |
Why?
|
| Pyrroles | 1 | 2004 | 576 | 0.050 |
Why?
|
| Viral Vaccines | 1 | 2003 | 304 | 0.050 |
Why?
|
| Cisplatin | 2 | 2004 | 2432 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2007 | 9180 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2003 | 657 | 0.040 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2020 | 134 | 0.040 |
Why?
|
| Intestines | 1 | 2004 | 686 | 0.040 |
Why?
|
| Lymphoma | 1 | 2008 | 1467 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 1996 | 7222 | 0.040 |
Why?
|
| Indoles | 1 | 2004 | 1009 | 0.040 |
Why?
|
| Prospective Studies | 5 | 2020 | 12873 | 0.040 |
Why?
|
| Thrombectomy | 1 | 1999 | 158 | 0.040 |
Why?
|
| Catheterization, Central Venous | 1 | 1991 | 354 | 0.040 |
Why?
|
| Mesothelioma | 1 | 2003 | 544 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2003 | 1090 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2007 | 8865 | 0.040 |
Why?
|
| Prognosis | 4 | 2013 | 21713 | 0.040 |
Why?
|
| Fluorescent Dyes | 1 | 2020 | 459 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2004 | 3005 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2009 | 3518 | 0.040 |
Why?
|
| Liver Diseases | 1 | 2002 | 574 | 0.040 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2010 | 2979 | 0.040 |
Why?
|
| Feasibility Studies | 3 | 2013 | 2292 | 0.040 |
Why?
|
| Peritoneal Neoplasms | 1 | 2003 | 821 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2003 | 1529 | 0.040 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2004 | 1415 | 0.040 |
Why?
|
| Pneumoperitoneum, Artificial | 1 | 1996 | 14 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2004 | 3890 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 2403 | 0.040 |
Why?
|
| Periodicals as Topic | 1 | 2021 | 338 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2007 | 3251 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 4892 | 0.030 |
Why?
|
| Neoplasm Staging | 4 | 2013 | 13658 | 0.030 |
Why?
|
| Disease Progression | 1 | 2007 | 6682 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2009 | 5178 | 0.030 |
Why?
|
| Radiology | 1 | 2021 | 434 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2004 | 4744 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2016 | 297 | 0.030 |
Why?
|
| Risk Factors | 3 | 2011 | 17523 | 0.030 |
Why?
|
| Dopamine | 1 | 1996 | 312 | 0.030 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 1993 | 16 | 0.030 |
Why?
|
| Algorithms | 1 | 2004 | 3890 | 0.030 |
Why?
|
| Medical Records | 2 | 2005 | 415 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2003 | 2819 | 0.030 |
Why?
|
| Methods | 1 | 1992 | 189 | 0.030 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2012 | 67 | 0.030 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2012 | 71 | 0.030 |
Why?
|
| Carcinoma | 1 | 2003 | 2578 | 0.030 |
Why?
|
| Punctures | 1 | 1992 | 104 | 0.030 |
Why?
|
| Young Adult | 4 | 2011 | 21445 | 0.030 |
Why?
|
| Animals | 6 | 2007 | 59536 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 3639 | 0.030 |
Why?
|
| Credentialing | 1 | 2011 | 63 | 0.020 |
Why?
|
| Chi-Square Distribution | 2 | 2007 | 1323 | 0.020 |
Why?
|
| Reproducibility of Results | 3 | 2008 | 6009 | 0.020 |
Why?
|
| Vena Cava, Inferior | 1 | 1992 | 190 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 4938 | 0.020 |
Why?
|
| Time Factors | 4 | 2011 | 12926 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2003 | 3552 | 0.020 |
Why?
|
| Aorta, Abdominal | 1 | 1991 | 152 | 0.020 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1993 | 340 | 0.020 |
Why?
|
| Plasmids | 1 | 2012 | 837 | 0.020 |
Why?
|
| Incidence | 1 | 2020 | 5673 | 0.020 |
Why?
|
| Kidney | 2 | 1996 | 2146 | 0.020 |
Why?
|
| Dogs | 1 | 1991 | 1155 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2012 | 6869 | 0.020 |
Why?
|
| Follow-Up Studies | 3 | 2013 | 14889 | 0.020 |
Why?
|
| Patient Selection | 1 | 2016 | 2055 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 383 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2012 | 1290 | 0.020 |
Why?
|
| Nephrectomy | 1 | 1993 | 779 | 0.020 |
Why?
|
| Portography | 1 | 2007 | 8 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2005 | 15862 | 0.020 |
Why?
|
| Medical Audit | 1 | 2008 | 188 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2003 | 16273 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 2003 | 4849 | 0.020 |
Why?
|
| Curriculum | 1 | 2011 | 860 | 0.020 |
Why?
|
| Administration, Topical | 1 | 1986 | 257 | 0.020 |
Why?
|
| Education, Medical, Graduate | 1 | 2011 | 671 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2009 | 1665 | 0.020 |
Why?
|
| 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 1 | 2005 | 13 | 0.020 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2005 | 17 | 0.020 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 1 | 2005 | 35 | 0.020 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2005 | 24 | 0.020 |
Why?
|
| Gelatin | 1 | 2005 | 49 | 0.020 |
Why?
|
| Acrylic Resins | 1 | 2005 | 43 | 0.020 |
Why?
|
| Propionates | 1 | 2004 | 71 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2005 | 162 | 0.020 |
Why?
|
| Tissue Fixation | 1 | 2005 | 136 | 0.020 |
Why?
|
| Tomography, Spiral Computed | 1 | 2005 | 133 | 0.020 |
Why?
|
| Benzamides | 1 | 2009 | 1832 | 0.020 |
Why?
|
| Laparoscopy | 1 | 1993 | 1225 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2004 | 176 | 0.010 |
Why?
|
| Dinoprostone | 1 | 2005 | 208 | 0.010 |
Why?
|
| Floxuridine | 1 | 2003 | 38 | 0.010 |
Why?
|
| Apoptosis | 2 | 2012 | 7591 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2003 | 197 | 0.010 |
Why?
|
| Hematologic Tests | 1 | 2003 | 82 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2005 | 471 | 0.010 |
Why?
|
| United States | 1 | 2021 | 15433 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2011 | 1270 | 0.010 |
Why?
|
| Rabbits | 1 | 2005 | 957 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2007 | 1546 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2003 | 334 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 2173 | 0.010 |
Why?
|
| Safety | 1 | 2005 | 465 | 0.010 |
Why?
|
| Markov Chains | 1 | 2003 | 175 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2004 | 700 | 0.010 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2003 | 171 | 0.010 |
Why?
|
| Vaccines, Attenuated | 1 | 2003 | 210 | 0.010 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2003 | 226 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2005 | 483 | 0.010 |
Why?
|
| Contraindications | 1 | 2002 | 150 | 0.010 |
Why?
|
| Vinblastine | 1 | 2003 | 453 | 0.010 |
Why?
|
| Leucovorin | 1 | 2003 | 332 | 0.010 |
Why?
|
| Caspases | 1 | 2005 | 661 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2009 | 1756 | 0.010 |
Why?
|
| Cause of Death | 1 | 2005 | 752 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2005 | 1519 | 0.010 |
Why?
|
| Benchmarking | 1 | 2003 | 273 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 4971 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2002 | 699 | 0.010 |
Why?
|
| Texas | 1 | 2011 | 6311 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 5159 | 0.010 |
Why?
|
| Bile Duct Neoplasms | 1 | 2005 | 493 | 0.010 |
Why?
|
| Monocytes | 1 | 2003 | 788 | 0.010 |
Why?
|
| Oligopeptides | 1 | 2002 | 429 | 0.010 |
Why?
|
| Hemolysis | 1 | 1999 | 127 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2003 | 945 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2010 | 2967 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2005 | 3536 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2003 | 1385 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2003 | 1944 | 0.010 |
Why?
|
| Length of Stay | 1 | 2005 | 1900 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2003 | 787 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 8873 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2008 | 5112 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2003 | 1694 | 0.010 |
Why?
|
| Dendritic Cells | 1 | 2003 | 1085 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 1879 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2013 | 5437 | 0.010 |
Why?
|
| Oliguria | 1 | 1996 | 18 | 0.010 |
Why?
|
| Central Venous Pressure | 1 | 1996 | 28 | 0.010 |
Why?
|
| Renal Circulation | 1 | 1996 | 60 | 0.010 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 1996 | 62 | 0.010 |
Why?
|
| Urine | 1 | 1996 | 143 | 0.010 |
Why?
|
| Cardiac Output | 1 | 1996 | 194 | 0.010 |
Why?
|
| Potassium | 1 | 1996 | 329 | 0.010 |
Why?
|
| Software | 1 | 2002 | 1321 | 0.010 |
Why?
|
| Cytokines | 1 | 2003 | 2809 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 7789 | 0.010 |
Why?
|
| Creatinine | 1 | 1996 | 531 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 7548 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2002 | 2086 | 0.010 |
Why?
|
| Electrocoagulation | 1 | 1993 | 65 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 6150 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2005 | 2027 | 0.010 |
Why?
|
| Esophageal and Gastric Varices | 1 | 1993 | 85 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 14551 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2004 | 7702 | 0.000 |
Why?
|
| Ovarian Neoplasms | 1 | 2003 | 4638 | 0.000 |
Why?
|
| Liver Transplantation | 1 | 1993 | 1112 | 0.000 |
Why?
|